Sanofi-aventis announced today that it has launched JEVTANA in combination with prednisone/prednisolone for the treatment of men with mHRPC previously treated with docetaxel. Men with this stage of cancer typically have a poor prognosis and until now, there have been no licensed treatments available to extend life.3

JEVTANA is the first licensed agent to significantly extend overall survival in men with mHRPC whose disease has progressed during or after treatment containing docetaxel (15.1 months median overall survival vs. 12.7 months in the control arm; HR=0.70 (95% CI: 0.59-0.83); P

Tag Cloud